• Non-clinical R&D activities to be wound down; resources to be focused on executing the Phase 2b trial
• Workforce reduced by approximately 60%; management and CEO salaries reduced
• Plan designed to substantially reduce cash burn
• Topline Phase 2b six-month endpoint data expected by mid-2027

Nes-Ziona, Israel, Oct. 19, 2026 (GLOBE NEWSWIRE) --  Enlivex Ltd. (NASDAQ:ENLV) ("Enlivex" or the "Company"), a quality longevity company powered by a prediction markets treasury, today announced a cost reduction plan, effective immediately, designed to substantially reduce the Company's cash burn and focus its resources on the execution of its Phase 2b clinical trial of Allocetra™ for the treatment of patients with moderate-to-severe age-related symptomatic primary knee osteoarthritis (OA). The Company expects to report topline six-month data from the trial by mid-2027.

The Company’s plan includes the following measures:

• Wind-down of non-clinical R&D: The Company is winding down, effective immediately, all research and development activities not related to the Phase 2b clinical trial.
• Focus on clinical execution: The Company's resources will be dedicated to the execution of the Phase 2b trial and related activities.
• Workforce reduction: The Company is reducing its workforce by approximately 60%.
• Management compensation reduction: Salaries for the Company's management team will be reduced by 20%, and the Chief Executive Officer’s will be reduced by 40%.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.